Verkuil, Arie Hans
E-Mail-Adresse
Geburtsdatum
Projekt
Organisationseinheiten
Berufsbeschreibung
Nachname
Vorname
Name
Suchergebnisse
Sustainability of social innovation hubs. Critical evaluation
2021, Al-Kilani, Mahmoud, Verkuil, Arie Hans, Meyer, Rolf
The fast pace of change brought on by advances of technology have led to significant pressure on companies to innovate to remain competitive and able to meet shareholders demands.
Case Study «Bureau Futur»
2020, Schulte, Volker, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc
Inkubatoren. Eine Analyse der Bedeutung und Qualität der Unterstützungsangebote von Inkubatoren für Start-ups im deutschsprachigen Raum
2014, Meyer, Rolf, Sidler, Adrian Urs, Verkuil, Arie Hans
Qualität und Effektivität der Angebote von Inkubatoren aus der Sicht des Managements der Inkubatoren sowie aus Sicht der geförderten Startups. Fokus auf Deutschschweiz und Deutschland.
Evaluating the key success factors of social business hubs in the Middle East
2021, Al-Kilani, Mahmoud, Verkuil, Arie Hans, Meyer, Rolf
Social business hubs play an important role in facilitating social innovation and support social entrepreneurs to deliver social benefits to the wider community. This paper aims to firstly identify and evaluate the key success factors of social business hubs in the Middle East with the focus on Jordan, Lebanon and Iraq, secondly, identify what successful social hubs offer, and thirdly, identify the challenges facing social business hubs in the region. In-depth interviews with eight social business hub managers were conducted using a pre-designed questionnaire. The findings were interesting and meaningful and show the impact severity of the COVID-19 pandemic on the infrastructure of the social business hubs. Networking and collaboration seem to be the predominant success factor for social business hubs. Finally, we observe that social business hubs in the region are facing many challenges; the main two are lack of government support and funding issues.
Case Study "Perseo Pharma"
2020, Kabous, Laila, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc
Founded in 2019, Perseo Pharma is a preclinical-stage biotech company with a unique asset for the development of enzyme therapies. Perseo Pharma possesses an innovative and proprietary enzyme shielding technology. Founded as independent spin-off of INOFEA AG, the company focuses on therapeutic enzymes for the treatment of cancer and rare genetic diseases. Over the past three decades, 30 therapeutic enzymes have been approved by EMA and FDA generating yearly 40bn. Therapeutic enzymes address a wide variety of indications, ranging from rare genetic diseases (enzyme replacement therapies) to oncology (key tumor-element depletion therapies). This offers biotech companies different opportunities and application fields for further development of enzyme therapeutics. The goal of this research is to analyze the case based on the 7-key model and provide recommendations on the financing opportunities available for Perseo pharma.
Case Study «Amunemi»
2020, Aeschbacher, Marc, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc
Start-ups. Aktuelle Case Studies für den Unterricht
2020, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc
Case Study «Derma2go»
2020, Eisenbart, Barbara, Verkuil, Arie Hans, Meyer, Rolf, Aeschbacher, Marc
Inkubatoren: Eine Analyse der Bedeutung und Qualität der Unterstützung von Inkubatoren für Start-ups im deutschsprachigen Raum
2014, Meyer, Rolf, Sidler, Adrian Urs, Verkuil, Arie Hans
Die Studie untersucht Inkubatoren im deutschsprachigen Raum und leitet Massnahmen zur optimalen Begleitung von Start-Ups ab.